Hem › Steatotisk leversjukdom › Arkansas
Kliniska studier för Steatotisk leversjukdom i Arkansas
8 studier för Steatotisk leversjukdom söker deltagare vid platser i Arkansas.
Städer i Arkansas
Officiell studietext (engelska)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Little Rock
- 89bio Clinical Study Site, North Little Rock
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06318169A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 30 sep. 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Little Rock
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 30 sep. 2026 · NCT07701993A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Arkansas Gastroenterology - North Little Rock, North Little Rock
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Little Rock
- Akero Clinical Study Site, North Little Rock
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Arkansas Gastroenterology, P.A, Little Rock
- ARcare Center for Clinical Research, Little Rock
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 9 sep. 2026 · NCT07288138A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Little Rock
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 27 juli 2026 · NCT07221227Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.